|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
47-1758322
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
108 Wilmot Road, Deerfield, Illinois
|
60015
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
þ
|
Accelerated filer ☐
|
Non-accelerated filer ☐ (Do not check if a smaller reporting company)
|
Smaller reporting company ☐
|
|
|
Item 1.
|
Consolidated Condensed Financial Statements (Unaudited)
|
||
|
|
a)
|
||
|
|
b)
|
||
|
|
c)
|
||
|
|
d)
|
||
|
|
e)
|
||
|
|
f)
|
||
|
Item 2.
|
|||
|
Item 3.
|
|||
|
Item 4.
|
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 5.
|
||
|
Item 6.
|
Item 1.
|
Consolidated Condensed Financial Statements (Unaudited)
|
|
February 28, 2017
|
|
August 31, 2016
|
||||
Assets
|
|
|
|
||||
Current Assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
11,822
|
|
|
$
|
9,807
|
|
Accounts receivable, net
|
5,674
|
|
|
6,260
|
|
||
Inventories
|
9,230
|
|
|
8,956
|
|
||
Other current assets
|
783
|
|
|
860
|
|
||
Total Current Assets
|
27,509
|
|
|
25,883
|
|
||
Non-Current Assets:
|
|
|
|
|
|
||
Property, plant and equipment, net
|
13,528
|
|
|
14,335
|
|
||
Goodwill
|
15,214
|
|
|
15,527
|
|
||
Intangible assets, net
|
9,650
|
|
|
10,302
|
|
||
Equity method investments (see Note 4)
|
6,164
|
|
|
6,174
|
|
||
Other non-current assets
|
440
|
|
|
467
|
|
||
Total Non-Current Assets
|
44,996
|
|
|
46,805
|
|
||
Total Assets
|
$
|
72,505
|
|
|
$
|
72,688
|
|
|
|
|
|
||||
Liabilities and Equity
|
|
|
|
|
|
||
Current Liabilities:
|
|
|
|
|
|
||
Short-term borrowings
|
$
|
1,153
|
|
|
$
|
323
|
|
Trade accounts payable (see Note 17)
|
11,264
|
|
|
11,000
|
|
||
Accrued expenses and other liabilities
|
4,935
|
|
|
5,484
|
|
||
Income taxes
|
326
|
|
|
206
|
|
||
Total Current Liabilities
|
17,678
|
|
|
17,013
|
|
||
Non-Current Liabilities:
|
|
|
|
|
|
||
Long-term debt
|
17,758
|
|
|
18,705
|
|
||
Deferred income taxes
|
2,339
|
|
|
2,644
|
|
||
Other non-current liabilities
|
4,309
|
|
|
4,045
|
|
||
Total Non-Current Liabilities
|
24,406
|
|
|
25,394
|
|
||
Commitments and Contingencies (see Note 9)
|
|
|
|
|
|
||
Equity:
|
|
|
|
|
|
||
Preferred stock $.01 par value; authorized 32 million shares, none issued
|
—
|
|
|
—
|
|
||
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 28, 2017 and August 31, 2016
|
12
|
|
|
12
|
|
||
Paid-in capital
|
10,162
|
|
|
10,111
|
|
||
Employee stock loan receivable
|
—
|
|
|
(1
|
)
|
||
Retained earnings
|
28,987
|
|
|
27,684
|
|
||
Accumulated other comprehensive (loss) income
|
(3,809
|
)
|
|
(2,992
|
)
|
||
Treasury stock, at cost; 91,818,244 shares at February 28, 2017 and 89,527,027 at August 31, 2016
|
(5,285
|
)
|
|
(4,934
|
)
|
||
Total Walgreens Boots Alliance, Inc. Shareholders’ Equity
|
30,067
|
|
|
29,880
|
|
||
Noncontrolling interests
|
354
|
|
|
401
|
|
||
Total Equity
|
30,421
|
|
|
30,281
|
|
||
Total Liabilities and Equity
|
$
|
72,505
|
|
|
$
|
72,688
|
|
|
Equity attributable to Walgreens Boots Alliance, Inc.
|
|
|
|
|
|||||||||||||||||||||||||||||
|
Common Stock
Shares
|
|
Common
Stock
Amount
|
|
Treasury
Stock
Amount
|
|
Paid-In
Capital
|
|
Employee
Stock
Loan
Receivable
|
|
Accumulated
Other
Comprehensive
(Loss) Income
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|
Total
Equity
|
|||||||||||||||||
August 31, 2016
|
1,082,986,591
|
|
|
$
|
12
|
|
|
$
|
(4,934
|
)
|
|
$
|
10,111
|
|
|
$
|
(1
|
)
|
|
$
|
(2,992
|
)
|
|
$
|
27,684
|
|
|
$
|
401
|
|
|
$
|
30,281
|
|
Net earnings
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,114
|
|
|
15
|
|
|
2,129
|
|
||||||||
Other comprehensive income (loss), net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(817
|
)
|
|
—
|
|
|
(43
|
)
|
|
(860
|
)
|
||||||||
Dividends declared ($0.750 per share)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(811
|
)
|
|
(6
|
)
|
|
(817
|
)
|
||||||||
Treasury stock purchases
|
(5,600,000
|
)
|
|
—
|
|
|
(457
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(457
|
)
|
||||||||
Employee stock purchase and option plans
|
3,308,783
|
|
|
—
|
|
|
106
|
|
|
10
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
117
|
|
||||||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
52
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
52
|
|
||||||||
Noncontrolling interests in businesses acquired
|
—
|
|
|
—
|
|
|
—
|
|
|
(11
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(13
|
)
|
|
(24
|
)
|
||||||||
February 28, 2017
|
1,080,695,374
|
|
|
$
|
12
|
|
|
$
|
(5,285
|
)
|
|
$
|
10,162
|
|
|
$
|
—
|
|
|
$
|
(3,809
|
)
|
|
$
|
28,987
|
|
|
$
|
354
|
|
|
$
|
30,421
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Sales
|
$
|
29,446
|
|
|
$
|
30,184
|
|
|
$
|
57,947
|
|
|
$
|
59,217
|
|
Cost of sales
|
21,885
|
|
|
22,317
|
|
|
43,270
|
|
|
43,931
|
|
||||
Gross Profit
|
7,561
|
|
|
7,867
|
|
|
14,677
|
|
|
15,286
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Selling, general and administrative expenses
|
6,124
|
|
|
6,007
|
|
|
11,810
|
|
|
11,958
|
|
||||
Equity earnings in AmerisourceBergen
|
42
|
|
|
—
|
|
|
59
|
|
|
—
|
|
||||
Operating Income
|
1,479
|
|
|
1,860
|
|
|
2,926
|
|
|
3,328
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Other expense
|
(15
|
)
|
|
(496
|
)
|
|
(14
|
)
|
|
(553
|
)
|
||||
Earnings Before Interest and Income Tax Provision
|
1,464
|
|
|
1,364
|
|
|
2,912
|
|
|
2,775
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Interest expense, net
|
172
|
|
|
140
|
|
|
345
|
|
|
278
|
|
||||
Earnings Before Income Tax Provision
|
1,292
|
|
|
1,224
|
|
|
2,567
|
|
|
2,497
|
|
||||
Income tax provision
|
246
|
|
|
301
|
|
|
466
|
|
|
468
|
|
||||
Post tax earnings from other equity method investments
|
16
|
|
|
9
|
|
|
28
|
|
|
20
|
|
||||
Net Earnings
|
1,062
|
|
|
932
|
|
|
2,129
|
|
|
2,049
|
|
||||
Net earnings attributable to noncontrolling interests
|
2
|
|
|
2
|
|
|
15
|
|
|
9
|
|
||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
$
|
1,060
|
|
|
$
|
930
|
|
|
$
|
2,114
|
|
|
$
|
2,040
|
|
|
|
|
|
|
|
|
|
||||||||
Net earnings per common share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
$
|
0.98
|
|
|
$
|
0.86
|
|
|
$
|
1.96
|
|
|
$
|
1.88
|
|
Diluted
|
$
|
0.98
|
|
|
$
|
0.85
|
|
|
$
|
1.94
|
|
|
$
|
1.87
|
|
|
|
|
|
|
|
|
|
||||||||
Dividends declared per share
|
$
|
0.375
|
|
|
$
|
0.360
|
|
|
$
|
0.750
|
|
|
$
|
0.720
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
1,079.7
|
|
|
1,080.2
|
|
|
1,080.9
|
|
|
1,084.6
|
|
||||
Diluted
|
1,085.5
|
|
|
1,088.4
|
|
|
1,086.9
|
|
|
1,093.5
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Comprehensive Income
|
|
|
|
|
|
|
|
||||||||
Net Earnings
|
$
|
1,062
|
|
|
$
|
932
|
|
|
$
|
2,129
|
|
|
$
|
2,049
|
|
|
|
|
|
|
|
|
|
||||||||
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|||||
Pension/postretirement obligations
|
5
|
|
|
(2
|
)
|
|
(4
|
)
|
|
1
|
|
||||
Unrealized gain on cash flow hedges
|
1
|
|
|
1
|
|
|
2
|
|
|
2
|
|
||||
Unrecognized loss on available-for-sale investments
|
—
|
|
|
(88
|
)
|
|
(1
|
)
|
|
(87
|
)
|
||||
Share of other comprehensive loss of equity method investments
|
(4
|
)
|
|
—
|
|
|
(5
|
)
|
|
—
|
|
||||
Currency translation adjustments
|
3
|
|
|
(1,156
|
)
|
|
(852
|
)
|
|
(1,606
|
)
|
||||
Total Other Comprehensive Income (Loss)
|
5
|
|
|
(1,245
|
)
|
|
(860
|
)
|
|
(1,690
|
)
|
||||
Total Comprehensive Income (Loss)
|
1,067
|
|
|
(313
|
)
|
|
1,269
|
|
|
359
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive income (loss) attributable to noncontrolling interests
|
5
|
|
|
(33
|
)
|
|
(28
|
)
|
|
(27
|
)
|
||||
Comprehensive Income (Loss) Attributable to Walgreens Boots Alliance, Inc.
|
$
|
1,062
|
|
|
$
|
(280
|
)
|
|
$
|
1,297
|
|
|
$
|
386
|
|
Net increase in cash and cash equivalents
|
2,015
|
|
|
586
|
|
||
Cash and cash equivalents at beginning of period
|
9,807
|
|
|
3,000
|
|
||
Cash and cash equivalents at end of period
|
$
|
11,822
|
|
|
$
|
3,586
|
|
Three Months Ended February 28, 2017
|
Retail Pharmacy USA
|
|
Retail Pharmacy International
|
|
Pharmaceutical Wholesale
|
|
Walgreens Boots Alliance, Inc.
|
||||||||
Asset impairments
|
$
|
65
|
|
|
$
|
1
|
|
|
$
|
1
|
|
|
$
|
67
|
|
Real estate costs
|
240
|
|
|
—
|
|
|
—
|
|
|
240
|
|
||||
Severance and other business transition and exit costs
|
11
|
|
|
18
|
|
|
4
|
|
|
33
|
|
||||
Total restructuring costs
|
$
|
316
|
|
|
$
|
19
|
|
|
$
|
5
|
|
|
$
|
340
|
|
|
|
|
|
|
|
|
|
||||||||
Three Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
||||
Asset impairments
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Real estate costs
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Severance and other business transition and exit costs
|
25
|
|
|
3
|
|
|
—
|
|
|
28
|
|
||||
Total restructuring costs
|
$
|
25
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
28
|
|
Six Months Ended February 28, 2017
|
Retail Pharmacy USA
|
|
Retail Pharmacy International
|
|
Pharmaceutical Wholesale
|
|
Walgreens Boots Alliance, Inc.
|
||||||||
Asset impairments
|
$
|
111
|
|
|
$
|
3
|
|
|
$
|
1
|
|
|
$
|
115
|
|
Real estate costs
|
249
|
|
|
—
|
|
|
—
|
|
|
249
|
|
||||
Severance and other business transition and exit costs
|
28
|
|
|
22
|
|
|
7
|
|
|
57
|
|
||||
Total restructuring costs
|
$
|
388
|
|
|
$
|
25
|
|
|
$
|
8
|
|
|
$
|
421
|
|
|
|
|
|
|
|
|
|
||||||||
Six Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
||||
Asset impairments
|
$
|
25
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
25
|
|
Real estate costs
|
52
|
|
|
—
|
|
|
—
|
|
|
52
|
|
||||
Severance and other business transition and exit costs
|
33
|
|
|
8
|
|
|
—
|
|
|
41
|
|
||||
Total restructuring costs
|
$
|
110
|
|
|
$
|
8
|
|
|
$
|
—
|
|
|
$
|
118
|
|
|
Asset
Impairments
|
|
Real estate
costs
|
|
Severance and
other business
transition and
exit costs
|
|
Total
|
||||||||
Balance at August 31, 2016
|
$
|
—
|
|
|
$
|
248
|
|
|
$
|
27
|
|
|
$
|
275
|
|
Restructuring Costs
|
115
|
|
|
249
|
|
|
57
|
|
|
421
|
|
||||
Payments
|
—
|
|
|
(28
|
)
|
|
(29
|
)
|
|
(57
|
)
|
||||
Other - non cash
|
(115
|
)
|
|
—
|
|
|
(13
|
)
|
|
(128
|
)
|
||||
Currency translation adjustments
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(1
|
)
|
||||
Balance at February 28, 2017
|
$
|
—
|
|
|
$
|
469
|
|
|
$
|
41
|
|
|
$
|
510
|
|
|
For the six months ended February 28, 2017
|
|
For the twelve months ended August 31, 2016
|
||||
Balance at beginning of period
|
$
|
466
|
|
|
$
|
446
|
|
Provision for present value of non-cancellable lease payments on closed facilities
|
258
|
|
|
134
|
|
||
Assumptions about future sublease income, terminations and changes in interest rates
|
(10
|
)
|
|
(34
|
)
|
||
Interest accretion
|
16
|
|
|
27
|
|
||
Cash payments, net of sublease income
|
(59
|
)
|
|
(107
|
)
|
||
Balance at end of period
|
$
|
671
|
|
|
$
|
466
|
|
|
February 28, 2017
|
|
August 31, 2016
|
||||||||
|
Carrying
Value
|
|
Ownership
Percentage
|
|
Carrying
Value
|
|
Ownership
Percentage
|
||||
AmerisourceBergen
|
$
|
4,982
|
|
|
26%
|
|
$
|
4,964
|
|
|
24%
|
Others
|
1,182
|
|
|
12% - 50%
|
|
1,210
|
|
|
12% - 50%
|
||
Total
|
$
|
6,164
|
|
|
|
|
$
|
6,174
|
|
|
|
|
Retail
Pharmacy USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||
August 31, 2016
|
$
|
9,036
|
|
|
$
|
3,369
|
|
|
$
|
3,122
|
|
|
$
|
15,527
|
|
Currency translation adjustments
|
—
|
|
|
(146
|
)
|
|
(167
|
)
|
|
(313
|
)
|
||||
February 28, 2017
|
$
|
9,036
|
|
|
$
|
3,223
|
|
|
$
|
2,955
|
|
|
$
|
15,214
|
|
|
February 28, 2017
|
|
August 31, 2016
|
||||
Gross Amortizable Intangible Assets
|
|
|
|
||||
Customer relationships and loyalty card holders
|
$
|
1,764
|
|
|
$
|
1,867
|
|
Purchased prescription files
|
718
|
|
|
932
|
|
||
Favorable lease interests and non-compete agreements
|
542
|
|
|
619
|
|
||
Trade names and trademarks
|
509
|
|
|
532
|
|
||
Purchasing and payer contracts
|
61
|
|
|
94
|
|
||
Total gross amortizable intangible assets
|
3,594
|
|
|
4,044
|
|
||
|
|
|
|
||||
Accumulated amortization
|
|
|
|
|
|
||
Customer relationships and loyalty card holders
|
$
|
328
|
|
|
$
|
275
|
|
Purchased prescription files
|
415
|
|
|
600
|
|
||
Favorable lease interests and non-compete agreements
|
344
|
|
|
388
|
|
||
Trade names and trademarks
|
129
|
|
|
105
|
|
||
Purchasing and payer contracts
|
39
|
|
|
71
|
|
||
Total accumulated amortization
|
1,255
|
|
|
1,439
|
|
||
Total amortizable intangible assets, net
|
$
|
2,339
|
|
|
$
|
2,605
|
|
|
|
|
|
||||
Indefinite lived Intangible Assets
|
|
|
|
|
|
||
Trade names and trademarks
|
$
|
5,323
|
|
|
$
|
5,604
|
|
Pharmacy licenses
|
1,988
|
|
|
2,093
|
|
||
Total indefinite lived intangible assets
|
$
|
7,311
|
|
|
$
|
7,697
|
|
|
|
|
|
||||
Total intangible assets, net
|
$
|
9,650
|
|
|
$
|
10,302
|
|
|
2017
|
|
2018
|
|
2019
|
|
2020
|
|
2021
|
||||||||||
Estimated annual amortization expense
|
$
|
357
|
|
|
$
|
326
|
|
|
$
|
295
|
|
|
$
|
236
|
|
|
$
|
194
|
|
|
February 28, 2017
|
|
August 31, 2016
|
||||
Short-Term Borrowings
(
1
)
|
|
|
|
||||
1.750% unsecured notes due November 2017
(
5
)(7)
|
$
|
748
|
|
|
$
|
—
|
|
Unsecured Pound Sterling variable rate term loan due 2019
|
90
|
|
|
63
|
|
||
Other
(2)
|
315
|
|
|
260
|
|
||
Total short-term borrowings
|
$
|
1,153
|
|
|
$
|
323
|
|
|
|
|
|
||||
Long-Term Debt
(1)
|
|
|
|
|
|
||
Unsecured Pound Sterling variable rate term loan due 2019
|
$
|
1,711
|
|
|
$
|
1,833
|
|
$6 Billion Note Issuance
(5)(7)
|
|
|
|
|
|
||
1.750% unsecured notes due 2018
|
1,247
|
|
|
1,246
|
|
||
2.600% unsecured notes due 2021
|
1,494
|
|
|
1,493
|
|
||
3.100% unsecured notes due 2023
|
745
|
|
|
744
|
|
||
3.450% unsecured notes due 2026
|
1,886
|
|
|
1,885
|
|
||
4.650% unsecured notes due 2046
|
590
|
|
|
590
|
|
||
$8 Billion Note Issuance
(5)(7)
|
|
|
|
|
|
||
1.750% unsecured notes due 2017
|
—
|
|
|
746
|
|
||
2.700% unsecured notes due 2019
|
1,245
|
|
|
1,244
|
|
||
3.300% unsecured notes due 2021
|
1,243
|
|
|
1,242
|
|
||
3.800% unsecured notes due 2024
|
1,987
|
|
|
1,987
|
|
||
4.500% unsecured notes due 2034
|
494
|
|
|
494
|
|
||
4.800% unsecured notes due 2044
|
1,492
|
|
|
1,492
|
|
||
£700 Million Note Issuance
(1)(5)(7)
|
|
|
|
|
|
||
2.875% unsecured Pound Sterling notes due 2020
|
495
|
|
|
521
|
|
||
3.600% unsecured Pound Sterling notes due 2025
|
371
|
|
|
391
|
|
||
€750 Million Note Issuance
(1)(5)(7)
|
|
|
|
|
|
||
2.125% unsecured Euro notes due 2026
|
790
|
|
|
830
|
|
||
$4 Billion Note Issuance
(6)(7)
|
|
|
|
|
|
||
3.100% unsecured notes due 2022
|
1,194
|
|
|
1,194
|
|
||
4.400% unsecured notes due 2042
|
492
|
|
|
492
|
|
||
$1 Billion Note Issuance
(6)(7)
|
|
|
|
|
|
||
5.250% unsecured notes due 2019
(3)
|
249
|
|
|
249
|
|
||
Other
(4)
|
33
|
|
|
32
|
|
||
Total long-term debt, less current portion
|
$
|
17,758
|
|
|
$
|
18,705
|
|
(1)
|
All notes are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated borrowings have been translated using the spot rates at
February 28, 2017
and
August 31, 2016
, respectively.
|
(2)
|
Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies.
|
(3)
|
Includes interest rate swap fair market value adjustments. See Note 8, Fair Value Measurements for additional fair value disclosures.
|
(4)
|
Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
|
(5)
|
Notes are unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding.
|
(6)
|
Notes are senior debt obligations of Walgreens and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance.
|
(7)
|
The fair value & carrying value of the
$6 billion
,
$8 billion
,
£0.7 billion
,
€0.75 billion
,
$4 billion
and
$1 billion
note issuances as of
February 28, 2017
was
$6.0 billion
&
$6.0 billion
,
$7.4 billion
&
$7.2 billion
,
$0.9 billion
&
$0.9 billion
,
$0.8 billion
&
$0.8 billion
,
$1.7 billion
&
$1.7 billion
and
$0.3 billion
&
$0.2 billion
, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market price and translated at the
February 28, 2017
spot rate, as applicable.
|
|
February 28, 2017
|
|
August 31, 2016
|
|
|
||||||||
|
Notional
(1)
|
|
Fair
Value
|
|
Notional
(1)
|
|
Fair
Value
|
|
Location in Consolidated
Condensed Balance Sheets
|
||||
Derivatives designated as fair value hedges:
|
|
|
|
|
|
|
|
|
|
||||
Interest rate swaps
|
250
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
Other non-current liabilities
|
Interest rate swaps
|
—
|
|
|
—
|
|
|
250
|
|
|
3
|
|
|
Other non-current assets
|
Derivatives not designated as hedges:
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency forwards
|
253
|
|
|
2
|
|
|
1,177
|
|
|
16
|
|
|
Other current assets
|
Foreign currency forwards
|
1,052
|
|
|
11
|
|
|
41
|
|
|
—
|
|
|
Other current liabilities
|
Basis swaps
|
2
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
Other current liabilities
|
Basis swaps
|
—
|
|
|
—
|
|
|
2
|
|
|
1
|
|
|
Other current assets
|
(1)
|
Amounts are presented in U.S. dollar equivalents, as applicable.
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
Location in Consolidated Condensed
Statements of Earnings
|
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Foreign currency forwards
|
Selling, general and administrative expense
|
|
$
|
(2
|
)
|
|
$
|
(23
|
)
|
|
$
|
47
|
|
|
$
|
(25
|
)
|
Foreign currency forwards
|
Other income (expense)
|
|
$
|
(15
|
)
|
|
$
|
33
|
|
|
$
|
(14
|
)
|
|
$
|
33
|
|
|
February 28, 2017
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets
:
|
|
|
|
|
|
|
|
||||||||
Restricted cash
(1)
|
$
|
170
|
|
|
$
|
170
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Money market funds
(2)
|
10,106
|
|
|
10,106
|
|
|
—
|
|
|
—
|
|
||||
Available-for-sale investments
(3)
|
28
|
|
|
28
|
|
|
—
|
|
|
—
|
|
||||
Foreign currency forwards
(4)
|
2
|
|
|
—
|
|
|
2
|
|
|
|
|
||||
Liabilities
:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency forwards
(4)
|
11
|
|
|
—
|
|
|
11
|
|
|
—
|
|
||||
Basis swaps
(4)
|
1
|
|
|
—
|
|
|
1
|
|
|
—
|
|
||||
Interest rate swaps
(5)
|
1
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
August 31, 2016
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets
:
|
|
|
|
|
|
|
|
||||||||
Restricted cash
(1)
|
$
|
185
|
|
|
$
|
185
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Money market funds
(2)
|
9,133
|
|
|
9,133
|
|
|
—
|
|
|
—
|
|
||||
Available-for-sale investments
(3)
|
32
|
|
|
32
|
|
|
—
|
|
|
—
|
|
||||
Interest rate swaps
(5)
|
3
|
|
|
—
|
|
|
3
|
|
|
—
|
|
||||
Foreign currency forwards
(4)
|
16
|
|
|
—
|
|
|
16
|
|
|
—
|
|
||||
Liabilities
:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basis swaps
(4)
|
1
|
|
|
—
|
|
|
1
|
|
|
—
|
|
(1)
|
Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
|
(2)
|
Money market funds are valued at the closing price reported by the fund sponsor.
|
(3)
|
Fair values of quoted investments are based on current bid prices as of the balance sheet dates.
|
(4)
|
The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
|
(5)
|
The fair value of interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 7, Financial Instruments for additional information.
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Service costs
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
2
|
|
Interest costs
|
43
|
|
|
77
|
|
|
86
|
|
|
159
|
|
||||
Expected returns on plan assets
|
(36
|
)
|
|
(62
|
)
|
|
(73
|
)
|
|
(127
|
)
|
||||
Curtailments
|
2
|
|
|
—
|
|
|
2
|
|
|
—
|
|
||||
Total net periodic pension costs
|
$
|
9
|
|
|
$
|
15
|
|
|
$
|
17
|
|
|
$
|
34
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Depreciation expense
|
$
|
332
|
|
|
$
|
346
|
|
|
$
|
666
|
|
|
$
|
644
|
|
Intangible asset and other amortization
|
81
|
|
|
96
|
|
|
165
|
|
|
180
|
|
||||
Total depreciation and amortization expense
|
$
|
413
|
|
|
$
|
442
|
|
|
$
|
831
|
|
|
$
|
824
|
|
|
Pension/ post-
retirement
obligations
|
|
Unrecognized
gain (loss) on
available-for-
sale
investments
|
|
Unrealized
gain (loss) on
cash flow
hedges
|
|
Share of
OCI of
equity
method
investments
|
|
Currency
translation
adjustment
|
|
Total
|
||||||||||||
Balance at November 30, 2016
|
$
|
(221
|
)
|
|
$
|
1
|
|
|
$
|
(36
|
)
|
|
$
|
(2
|
)
|
|
$
|
(3,552
|
)
|
|
$
|
(3,810
|
)
|
Other comprehensive income (loss) before reclassification adjustments
|
6
|
|
|
—
|
|
|
—
|
|
|
(7
|
)
|
|
(1
|
)
|
|
(2
|
)
|
||||||
Amounts reclassified from accumulated OCI
|
—
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
1
|
|
||||||
Tax benefit (provision)
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
3
|
|
|
—
|
|
|
2
|
|
||||||
Net other comprehensive income (loss)
|
5
|
|
|
—
|
|
|
1
|
|
|
(4
|
)
|
|
(1
|
)
|
|
1
|
|
||||||
Balance at February 28, 2017
|
$
|
(216
|
)
|
|
$
|
1
|
|
|
$
|
(35
|
)
|
|
$
|
(6
|
)
|
|
$
|
(3,553
|
)
|
|
$
|
(3,809
|
)
|
|
Pension/ post-
retirement
obligations
|
|
Unrecognized
gain (loss) on
available-for-
sale
investments
|
|
Unrealized
gain (loss) on
cash flow
hedges
|
|
Share of
OCI of
equity
method
investments
|
|
Currency
translation
adjustment
|
|
Total
|
||||||||||||
Balance at August 31, 2016
|
$
|
(212
|
)
|
|
$
|
2
|
|
|
$
|
(37
|
)
|
|
$
|
(1
|
)
|
|
$
|
(2,744
|
)
|
|
$
|
(2,992
|
)
|
Other comprehensive income (loss) before reclassification adjustments
|
(5
|
)
|
|
(1
|
)
|
|
—
|
|
|
(8
|
)
|
|
(809
|
)
|
|
(823
|
)
|
||||||
Amounts reclassified from accumulated OCI
|
—
|
|
|
—
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||||
Tax benefit (provision)
|
1
|
|
|
—
|
|
|
(1
|
)
|
|
3
|
|
|
—
|
|
|
3
|
|
||||||
Net other comprehensive income (loss)
|
(4
|
)
|
|
(1
|
)
|
|
2
|
|
|
(5
|
)
|
|
(809
|
)
|
|
(817
|
)
|
||||||
Balance at February 28, 2017
|
$
|
(216
|
)
|
|
$
|
1
|
|
|
$
|
(35
|
)
|
|
$
|
(6
|
)
|
|
$
|
(3,553
|
)
|
|
$
|
(3,809
|
)
|
|
Pension/ post-
retirement
obligations
|
|
Unrecognized
gain (loss) on
available-for-
sale
investments
|
|
Unrealized
gain (loss) on
cash flow
hedges
|
|
Share of
OCI of
equity
method
investments
|
|
Currency
translation
adjustment
|
|
Total
|
||||||||||||
Balance at November 30, 2015
|
$
|
32
|
|
|
$
|
260
|
|
|
$
|
(39
|
)
|
|
$
|
—
|
|
|
$
|
(911
|
)
|
|
$
|
(658
|
)
|
Other comprehensive income (loss) before reclassification adjustments
|
(4
|
)
|
|
(139
|
)
|
|
—
|
|
|
—
|
|
|
(1,121
|
)
|
|
(1,264
|
)
|
||||||
Amounts reclassified from accumulated OCI
|
—
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|
—
|
|
|
2
|
|
||||||
Tax benefit (provision)
|
2
|
|
|
51
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
52
|
|
||||||
Net other comprehensive income (loss)
|
(2
|
)
|
|
(88
|
)
|
|
1
|
|
|
—
|
|
|
(1,121
|
)
|
|
(1,210
|
)
|
||||||
Balance at February 29, 2016
|
$
|
30
|
|
|
$
|
172
|
|
|
$
|
(38
|
)
|
|
$
|
—
|
|
|
$
|
(2,032
|
)
|
|
$
|
(1,868
|
)
|
|
Pension/ post-
retirement
obligations
|
|
Unrecognized
gain (loss) on
available-for-
sale
investments
|
|
Unrealized
gain (loss) on
cash flow
hedges
|
|
Share of
OCI of
equity
method
investments
|
|
Currency
translation
adjustment
|
|
Total
|
||||||||||||
Balance at August 31, 2015
|
$
|
29
|
|
|
$
|
259
|
|
|
$
|
(40
|
)
|
|
$
|
—
|
|
|
$
|
(462
|
)
|
|
$
|
(214
|
)
|
Other comprehensive income (loss) before reclassification adjustments
|
(1
|
)
|
|
(144
|
)
|
|
—
|
|
|
—
|
|
|
(1,570
|
)
|
|
(1,715
|
)
|
||||||
Amounts reclassified from accumulated OCI
|
—
|
|
|
—
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||||
Tax benefit (provision)
|
2
|
|
|
57
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
58
|
|
||||||
Net other comprehensive income (loss)
|
1
|
|
|
(87
|
)
|
|
2
|
|
|
—
|
|
|
(1,570
|
)
|
|
(1,654
|
)
|
||||||
Balance at February 29, 2016
|
$
|
30
|
|
|
$
|
172
|
|
|
$
|
(38
|
)
|
|
$
|
—
|
|
|
$
|
(2,032
|
)
|
|
$
|
(1,868
|
)
|
•
|
The Retail Pharmacy USA segment consists of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.
|
•
|
The Retail Pharmacy International segment consists primarily of pharmacy-led health and beauty stores and optical practices. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, the Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.
|
•
|
The Pharmaceutical Wholesale segment consists of pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen reported on a two-month lag. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.
|
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Three Months Ended February 28, 2017
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales to external customers
|
$
|
21,814
|
|
|
$
|
3,101
|
|
|
$
|
4,531
|
|
|
$
|
—
|
|
|
$
|
29,446
|
|
Intersegment sales
|
—
|
|
|
—
|
|
|
499
|
|
|
(499
|
)
|
|
—
|
|
|||||
Sales
|
$
|
21,814
|
|
|
$
|
3,101
|
|
|
$
|
5,030
|
|
|
$
|
(499
|
)
|
|
$
|
29,446
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
1,552
|
|
|
$
|
242
|
|
|
$
|
226
|
|
|
$
|
(4
|
)
|
|
$
|
2,016
|
|
Three Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Sales to external customers
|
$
|
21,500
|
|
|
$
|
3,627
|
|
|
$
|
5,057
|
|
|
$
|
—
|
|
|
$
|
30,184
|
|
Intersegment sales
|
—
|
|
|
1
|
|
|
570
|
|
|
(571
|
)
|
|
—
|
|
|||||
Sales
|
$
|
21,500
|
|
|
$
|
3,628
|
|
|
$
|
5,627
|
|
|
$
|
(571
|
)
|
|
$
|
30,184
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
1,632
|
|
|
$
|
335
|
|
|
$
|
155
|
|
|
$
|
(2
|
)
|
|
$
|
2,120
|
|
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Six Months Ended February 28, 2017
|
|
|
|
|
|
|
|
|
|
||||||||||
Sales to external customers
|
$
|
42,473
|
|
|
$
|
6,063
|
|
|
$
|
9,411
|
|
|
$
|
—
|
|
|
$
|
57,947
|
|
Intersegment sales
|
—
|
|
|
—
|
|
|
1,036
|
|
|
(1,036
|
)
|
|
—
|
|
|||||
Sales
|
$
|
42,473
|
|
|
$
|
6,063
|
|
|
$
|
10,447
|
|
|
$
|
(1,036
|
)
|
|
$
|
57,947
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
2,841
|
|
|
$
|
455
|
|
|
$
|
450
|
|
|
$
|
(4
|
)
|
|
$
|
3,742
|
|
Six Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Sales to external customers
|
$
|
41,870
|
|
|
$
|
7,086
|
|
|
$
|
10,261
|
|
|
$
|
—
|
|
|
$
|
59,217
|
|
Intersegment sales
|
—
|
|
|
1
|
|
|
1,162
|
|
|
(1,163
|
)
|
|
—
|
|
|||||
Sales
|
$
|
41,870
|
|
|
$
|
7,087
|
|
|
$
|
11,423
|
|
|
$
|
(1,163
|
)
|
|
$
|
59,217
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
2,875
|
|
|
$
|
650
|
|
|
$
|
321
|
|
|
$
|
(7
|
)
|
|
$
|
3,839
|
|
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Three Months Ended February 28, 2017
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
1,552
|
|
|
$
|
242
|
|
|
$
|
226
|
|
|
$
|
(4
|
)
|
|
$
|
2,016
|
|
Cost transformation
|
|
|
|
|
|
|
|
|
|
|
|
|
(340
|
)
|
|||||
Acquisition-related amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
(82
|
)
|
|||||
LIFO provision
|
|
|
|
|
|
|
|
|
|
|
|
|
(49
|
)
|
|||||
Adjustments to equity earnings in AmerisourceBergen
|
|
|
|
|
|
|
|
|
|
|
|
|
(37
|
)
|
|||||
Acquisition-related costs
|
|
|
|
|
|
|
|
|
|
|
|
|
(29
|
)
|
|||||
Operating Income
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,479
|
|
||||
Three Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted Operating Income
|
$
|
1,632
|
|
|
$
|
335
|
|
|
$
|
155
|
|
|
$
|
(2
|
)
|
|
$
|
2,120
|
|
Cost transformation
|
|
|
|
|
|
|
|
|
|
|
|
|
(28
|
)
|
|||||
Acquisition-related amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
(101
|
)
|
|||||
LIFO provision
|
|
|
|
|
|
|
|
|
|
|
|
|
(68
|
)
|
|||||
Acquisition-related costs
|
|
|
|
|
|
|
|
|
(33
|
)
|
|||||||||
Asset impairment
|
|
|
|
|
|
|
|
|
|
|
|
|
(30
|
)
|
|||||
Operating Income
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,860
|
|
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Six Months Ended February 28, 2017
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted Operating Income
|
$
|
2,841
|
|
|
$
|
455
|
|
|
$
|
450
|
|
|
$
|
(4
|
)
|
|
$
|
3,742
|
|
Cost transformation
|
|
|
|
|
|
|
|
|
|
|
|
|
(421
|
)
|
|||||
Acquisition-related amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
(164
|
)
|
|||||
LIFO provision
|
|
|
|
|
|
|
|
|
|
|
|
|
(107
|
)
|
|||||
Adjustments to equity earnings in AmerisourceBergen
|
|
|
|
|
|
|
|
|
|
|
|
|
(78
|
)
|
|||||
Acquisition-related costs
|
|
|
|
|
|
|
|
|
|
|
|
|
(46
|
)
|
|||||
Operating Income
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,926
|
|
||||
Six Months Ended February 29, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted Operating Income
|
$
|
2,875
|
|
|
$
|
650
|
|
|
$
|
321
|
|
|
$
|
(7
|
)
|
|
$
|
3,839
|
|
Cost transformation
|
|
|
|
|
|
|
|
|
|
|
|
|
(118
|
)
|
|||||
Acquisition-related amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
(182
|
)
|
|||||
LIFO provision
|
|
|
|
|
|
|
|
|
|
|
|
|
(114
|
)
|
|||||
Acquisition-related costs
|
|
|
|
|
|
|
|
|
(67
|
)
|
|||||||||
Asset impairment
|
|
|
|
|
|
|
|
|
|
|
|
|
(30
|
)
|
|||||
Operating Income
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,328
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Purchases, net
|
$
|
10,602
|
|
|
$
|
10,481
|
|
|
$
|
21,238
|
|
|
$
|
20,804
|
|
|
February 28, 2017
|
|
August 31, 2016
|
||||
Trade accounts payable, net
|
$
|
4,207
|
|
|
$
|
3,456
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
•
|
Retail Pharmacy USA;
|
•
|
Retail Pharmacy International; and
|
•
|
Pharmaceutical Wholesale
|
|
(in millions, except per share amounts)
|
||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Sales
|
$
|
29,446
|
|
|
$
|
30,184
|
|
|
$
|
57,947
|
|
|
$
|
59,217
|
|
Gross Profit
(2)
|
7,561
|
|
|
7,867
|
|
|
14,677
|
|
|
15,286
|
|
||||
Selling, general and administrative expenses
(2)
|
6,124
|
|
|
6,007
|
|
|
11,810
|
|
|
11,958
|
|
||||
Operating Income
|
1,479
|
|
|
1,860
|
|
|
2,926
|
|
|
3,328
|
|
||||
Adjusted Operating Income (Non-GAAP measure)
(1)
|
2,016
|
|
|
2,120
|
|
|
3,742
|
|
|
3,839
|
|
||||
Earnings Before Interest and Income Tax Provision
|
1,464
|
|
|
1,364
|
|
|
2,912
|
|
|
2,775
|
|
||||
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
1,060
|
|
|
930
|
|
|
2,114
|
|
|
2,040
|
|
||||
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)
(1)
|
1,476
|
|
|
1,423
|
|
|
2,677
|
|
|
2,555
|
|
||||
Net earnings per common share – diluted
|
0.98
|
|
|
0.85
|
|
|
1.94
|
|
|
1.87
|
|
||||
Adjusted net earnings per common share – diluted (Non-GAAP measure)
(1)
|
1.36
|
|
|
1.31
|
|
|
2.46
|
|
|
2.34
|
|
|
Percentage Increases (Decreases) from Prior Year
|
||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||
Sales
|
(2.4
|
)
|
|
13.6
|
|
|
(2.1
|
)
|
|
28.4
|
|
Gross Profit
(2)
|
(3.9
|
)
|
|
15.0
|
|
|
(4.0
|
)
|
|
25.9
|
|
Selling, general and administrative expenses
(2)
|
1.9
|
|
|
7.9
|
|
|
(1.2
|
)
|
|
19.3
|
|
Operating Income
|
(20.5
|
)
|
|
35.1
|
|
|
(12.1
|
)
|
|
36.9
|
|
Adjusted Operating Income (Non-GAAP measure)
(1)
|
(4.9
|
)
|
|
15.2
|
|
|
(2.5
|
)
|
|
29.8
|
|
Earnings Before Interest and Income Tax Provision
|
7.3
|
|
|
(47.3
|
)
|
|
4.9
|
|
|
(27.7
|
)
|
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
|
14.0
|
|
|
(54.5
|
)
|
|
3.6
|
|
|
(29.5
|
)
|
Adjusted Net Earnings Attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)
(1)
|
3.7
|
|
|
14.4
|
|
|
4.8
|
|
|
28.2
|
|
Net earnings per common share – diluted
|
15.3
|
|
|
(56.0
|
)
|
|
3.7
|
|
|
(35.1
|
)
|
Adjusted net earnings per common share – diluted (Non-GAAP measure)
(1)
|
3.8
|
|
|
11.0
|
|
|
5.1
|
|
|
18.2
|
|
|
Percent to Sales
|
||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
Gross Margin
(2)
|
25.7
|
|
26.1
|
|
25.3
|
|
25.8
|
Selling, general and administrative expenses
(2)
|
20.8
|
|
19.9
|
|
20.4
|
|
20.2
|
(1)
|
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with generally accepted accounting principles in the United States (“GAAP”).
|
(2)
|
To improve comparability, certain classification changes were made to prior period Sales, Cost of sales and Selling, general and administrative expenses. These changes had no impact on Operating Income or Adjusted Operating Income. The reclassifications were made in the fourth quarter of fiscal 2016.
|
|
(in millions, except location amounts)
|
||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Sales
|
$
|
21,814
|
|
|
$
|
21,500
|
|
|
$
|
42,473
|
|
|
$
|
41,870
|
|
Gross Profit
|
5,876
|
|
|
5,895
|
|
|
11,315
|
|
|
11,340
|
|
||||
Selling, general and administrative expenses
|
4,756
|
|
|
4,466
|
|
|
9,090
|
|
|
8,883
|
|
||||
Operating Income
|
1,120
|
|
|
1,429
|
|
|
2,225
|
|
|
2,457
|
|
||||
Adjusted Operating Income (Non-GAAP measure)
(1)
|
1,552
|
|
|
1,632
|
|
|
2,841
|
|
|
2,875
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Number of Prescriptions
(2)
|
192.7
|
|
|
186.7
|
|
|
379.9
|
|
|
372.6
|
|
||||
30-Day Equivalent Prescriptions
(2)(3)
|
246.7
|
|
|
232.9
|
|
|
484.2
|
|
|
463.6
|
|
||||
Number of Locations at period end
|
8,126
|
|
|
8,196
|
|
|
8,126
|
|
|
8,196
|
|
|
Percentage Increases (Decreases) from Prior Year
|
||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||
Sales
|
1.5
|
|
|
2.1
|
|
|
1.4
|
|
|
3.1
|
|
Gross Profit
|
(0.3
|
)
|
|
2.6
|
|
|
(0.2
|
)
|
|
2.7
|
|
Selling, general and administrative expenses
|
6.5
|
|
|
(2.0
|
)
|
|
2.3
|
|
|
(1.4
|
)
|
Operating Income
|
(21.6
|
)
|
|
10.6
|
|
|
(9.4
|
)
|
|
4.7
|
|
Adjusted Operating Income (Non-GAAP measure)
(1)
|
(4.9
|
)
|
|
2.1
|
|
|
(1.2
|
)
|
|
5.9
|
|
Comparable Store Sales
(4)
|
2.4
|
|
|
2.2
|
|
|
1.8
|
|
|
4.0
|
|
Pharmacy Sales
|
3.7
|
|
|
3.2
|
|
|
3.1
|
|
|
4.9
|
|
Comparable Pharmacy Sales
(4)
|
4.2
|
|
|
3.7
|
|
|
3.0
|
|
|
6.5
|
|
Retail Sales
|
(2.7
|
)
|
|
0.3
|
|
|
(1.9
|
)
|
|
(0.3
|
)
|
Comparable Retail Sales
(4)
|
(0.8
|
)
|
|
(0.3
|
)
|
|
(0.7
|
)
|
|
(0.4
|
)
|
Comparable Number of Prescriptions
(2)(4)
|
5.2
|
|
|
1.3
|
|
|
3.1
|
|
|
2.4
|
|
Comparable 30-Day Equivalent Prescriptions
(2)(3)(4)
|
7.9
|
|
|
2.8
|
|
|
5.7
|
|
|
3.8
|
|
|
Percent to Sales
|
||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
Gross Margin
|
26.9
|
|
27.4
|
|
26.6
|
|
27.1
|
Selling, general and administrative expenses
|
21.8
|
|
20.8
|
|
21.4
|
|
21.2
|
(1)
|
See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable GAAP measure and related disclosures.
|
(2)
|
Includes immunizations.
|
(3)
|
Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
|
(4)
|
Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or subject to a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the industries in which we operate. As a result, our method of calculating comparable sales may not be the same as other companies’ methods. Comparable sales and comparable prescription figures are adjusted for the leap year by including only the first 28 days of February 2016.
|
|
(in millions, except location amounts)
|
||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Sales
(4)
|
$
|
3,101
|
|
|
$
|
3,628
|
|
|
$
|
6,063
|
|
|
$
|
7,087
|
|
Gross Profit
(4)
|
1,204
|
|
|
1,439
|
|
|
2,379
|
|
|
2,861
|
|
||||
Selling, general and administrative expenses
(4)
|
1,006
|
|
|
1,140
|
|
|
1,999
|
|
|
2,260
|
|
||||
Operating Income
|
198
|
|
|
299
|
|
|
380
|
|
|
601
|
|
||||
Adjusted Operating Income (Non-GAAP measure)
(1)
|
242
|
|
|
335
|
|
|
455
|
|
|
650
|
|
||||
Number of Locations at period end
|
4,701
|
|
|
4,603
|
|
|
4,701
|
|
|
4,603
|
|
|
Percentage Increases (Decreases) from Prior Year
|
||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||
Sales
(4)
|
(14.5
|
)
|
|
NA
|
|
(14.4
|
)
|
|
NA
|
Gross Profit
(4)
|
(16.3
|
)
|
|
NA
|
|
(16.8
|
)
|
|
NA
|
Selling, general and administrative expenses
(4)
|
(11.8
|
)
|
|
NA
|
|
(11.5
|
)
|
|
NA
|
Operating Income
|
(33.8
|
)
|
|
NA
|
|
(36.8
|
)
|
|
NA
|
Adjusted Operating Income (Non-GAAP measure)
(1)
|
(27.8
|
)
|
|
NA
|
|
(30.0
|
)
|
|
NA
|
Comparable Store Sales
(2)
|
(13.7
|
)
|
|
NA
|
|
(14.3
|
)
|
|
NA
|
Comparable Store Sales in constant currency
(2)(3)
|
(0.9
|
)
|
|
NA
|
|
(0.5
|
)
|
|
NA
|
Pharmacy Sales
(4)
|
(15.6
|
)
|
|
NA
|
|
(14.9
|
)
|
|
NA
|
Comparable Pharmacy Sales
(2)
|
(15.4
|
)
|
|
NA
|
|
(15.0
|
)
|
|
NA
|
Comparable Pharmacy Sales in constant currency
(2)(3)
|
(3.7
|
)
|
|
NA
|
|
(2.1
|
)
|
|
NA
|
Retail Sales
(4)
|
(14.0
|
)
|
|
NA
|
|
(14.2
|
)
|
|
NA
|
Comparable Retail Sales
(2)
|
(12.8
|
)
|
|
NA
|
|
(13.8
|
)
|
|
NA
|
Comparable Retail Sales in constant currency
(2)(3)
|
0.6
|
|
|
NA
|
|
0.4
|
|
|
NA
|
|
Percent to Sales
|
||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
Gross Margin
(4)
|
38.8
|
|
39.7
|
|
39.2
|
|
40.4
|
Selling, general and administrative expenses
(4)
|
32.4
|
|
31.4
|
|
33.0
|
|
31.9
|
NA
|
Not applicable
|
(1)
|
See “--Non-GAAP Measures” below for reconciliations to the most directly comparable GAAP measure and related disclosures.
|
(2)
|
Comparable stores are defined as those that have been open for at least twelve consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past twelve months. Relocated and acquired stores are not included as comparable stores for the first twelve months after the relocation or acquisition. The method of calculating comparable sales varies across the industries in which we operate. As a result, our method of calculating comparable sales may not be the same as other companies’ methods. The three and six month periods ended February 29, 2016 figures include an adjustment to remove February 29, 2016 results due to the leap year.
|
(3)
|
The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and this presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. See “--Non-GAAP Measures” below.
|
(4)
|
To improve comparability, certain classification changes were made to prior period Sales, Cost of sales and Selling, general and administrative expenses. These changes had no impact on Operating Income or Adjusted Operating Income. The reclassifications were made in the fourth quarter of fiscal 2016.
|
|
(in millions, except location amounts)
|
||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Sales
|
$
|
5,030
|
|
|
$
|
5,627
|
|
|
$
|
10,447
|
|
|
$
|
11,423
|
|
Gross Profit
|
485
|
|
|
535
|
|
|
987
|
|
|
1,092
|
|
||||
Selling, general and administrative expenses
|
362
|
|
|
401
|
|
|
721
|
|
|
815
|
|
||||
Equity earnings in AmerisourceBergen
|
42
|
|
|
—
|
|
|
59
|
|
|
—
|
|
||||
Operating Income
|
165
|
|
|
134
|
|
|
325
|
|
|
277
|
|
||||
Adjusted Operating Income (Non-GAAP measure)
(1)
|
226
|
|
|
155
|
|
|
450
|
|
|
321
|
|
|
Percentage Increases (Decreases) from Prior Year
|
||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||
Sales
|
(10.6
|
)
|
|
NA
|
|
(8.5
|
)
|
|
NA
|
Gross Profit
|
(9.3
|
)
|
|
NA
|
|
(9.6
|
)
|
|
NA
|
Selling, general and administrative expenses
|
(9.7
|
)
|
|
NA
|
|
(11.5
|
)
|
|
NA
|
Operating Income
|
23.1
|
|
|
NA
|
|
17.3
|
|
|
NA
|
Adjusted Operating Income (Non-GAAP measure)
(1)
|
45.8
|
|
|
NA
|
|
40.2
|
|
|
NA
|
Comparable Sales
(2)
|
(6.5
|
)
|
|
NA
|
|
(4.6
|
)
|
|
NA
|
Comparable Sales in constant currency
(2)(3)
|
5.2
|
|
|
NA
|
|
5.0
|
|
|
NA
|
|
Percent to Sales
|
||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
Gross Margin
|
9.6
|
|
9.5
|
|
9.4
|
|
9.6
|
Selling, general and administrative expenses
|
7.2
|
|
7.1
|
|
6.9
|
|
7.1
|
NA
|
Not applicable
|
(1)
|
See “--Non-GAAP Measures” below for reconciliations to the most directly comparable GAAP measure and related disclosures.
|
(2)
|
Comparable sales are defined as sales excluding acquisitions and dispositions. The three and six month periods ended February 29, 2016 figures include an adjustment to remove February 29, 2016 results due to the leap year.
|
(3)
|
The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the United States reporting in currencies other than the U.S. dollar and this presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. See “--Non-GAAP Measures” below.
|
|
(in millions)
|
||||||||||||||||||
|
Three Months Ended February 29, 2016
|
||||||||||||||||||
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Operating Income (GAAP)
|
$
|
1,429
|
|
|
$
|
299
|
|
|
$
|
134
|
|
|
$
|
(2
|
)
|
|
$
|
1,860
|
|
Cost transformation
|
25
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
28
|
|
|||||
Acquisition-related amortization
|
47
|
|
|
33
|
|
|
21
|
|
|
—
|
|
|
101
|
|
|||||
LIFO provision
|
68
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
68
|
|
|||||
Acquisition-related costs
|
33
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
33
|
|
|||||
Asset impairment
|
30
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
30
|
|
|||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
1,632
|
|
|
$
|
335
|
|
|
$
|
155
|
|
|
$
|
(2
|
)
|
|
$
|
2,120
|
|
|
(in millions)
|
||||||||||||||||||
|
Six Months Ended February 28, 2017
|
||||||||||||||||||
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Operating Income (GAAP)
|
$
|
2,225
|
|
|
$
|
380
|
|
|
$
|
325
|
|
|
$
|
(4
|
)
|
|
$
|
2,926
|
|
Cost transformation
|
388
|
|
|
25
|
|
|
8
|
|
|
—
|
|
|
421
|
|
|||||
Acquisition-related amortization
|
75
|
|
|
50
|
|
|
39
|
|
|
—
|
|
|
164
|
|
|||||
LIFO provision
|
107
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
107
|
|
|||||
Adjustments to equity earnings in AmerisourceBergen
|
—
|
|
|
—
|
|
|
78
|
|
|
—
|
|
|
78
|
|
|||||
Acquisition-related costs
|
46
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
46
|
|
|||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
2,841
|
|
|
$
|
455
|
|
|
$
|
450
|
|
|
$
|
(4
|
)
|
|
$
|
3,742
|
|
|
(in millions)
|
||||||||||||||||||
|
Six Months Ended February 29, 2016
|
||||||||||||||||||
|
Retail
Pharmacy
USA
|
|
Retail
Pharmacy
International
|
|
Pharmaceutical
Wholesale
|
|
Eliminations
|
|
Walgreens
Boots
Alliance, Inc.
|
||||||||||
Operating Income (GAAP)
|
$
|
2,457
|
|
|
$
|
601
|
|
|
$
|
277
|
|
|
$
|
(7
|
)
|
|
$
|
3,328
|
|
Cost transformation
|
110
|
|
|
8
|
|
|
—
|
|
|
—
|
|
|
118
|
|
|||||
Acquisition-related amortization
|
97
|
|
|
41
|
|
|
44
|
|
|
—
|
|
|
182
|
|
|||||
LIFO provision
|
114
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
114
|
|
|||||
Acquisition-related costs
|
67
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
67
|
|
|||||
Asset impairment
|
30
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
30
|
|
|||||
Adjusted Operating Income (Non-GAAP measure)
|
$
|
2,875
|
|
|
$
|
650
|
|
|
$
|
321
|
|
|
$
|
(7
|
)
|
|
$
|
3,839
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
February 28, 2017
|
|
February 29, 2016
|
|
February 28, 2017
|
|
February 29, 2016
|
||||||||
Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP)
|
$
|
1,060
|
|
|
$
|
930
|
|
|
$
|
2,114
|
|
|
$
|
2,040
|
|
|
|
|
|
|
|
|
|
||||||||
Adjustments to Operating Income:
|
|
|
|
|
|
|
|
||||||||
Cost transformation
|
340
|
|
|
28
|
|
|
421
|
|
|
118
|
|
||||
Acquisition-related amortization
(1)
|
82
|
|
|
101
|
|
|
164
|
|
|
182
|
|
||||
LIFO provision
(1)
|
49
|
|
|
68
|
|
|
107
|
|
|
114
|
|
||||
Adjustments to equity earnings in AmerisourceBergen
(1)
|
37
|
|
|
—
|
|
|
78
|
|
|
—
|
|
||||
Acquisition-related costs
(1)
|
29
|
|
|
33
|
|
|
46
|
|
|
67
|
|
||||
Asset impairment
(1)
|
—
|
|
|
30
|
|
|
—
|
|
|
30
|
|
||||
Total Adjustments to Operating Income
|
537
|
|
|
260
|
|
|
816
|
|
|
511
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Adjustments to Other income (expense):
|
|
|
|
|
|
|
|
||||||||
Decrease in fair market value of AmerisourceBergen warrants
(1)
|
—
|
|
|
529
|
|
|
—
|
|
|
586
|
|
||||
Net investment hedging (gain) loss
(1)
|
15
|
|
|
(33
|
)
|
|
14
|
|
|
(33
|
)
|
||||
Total Adjustments to Other income (expense)
|
15
|
|
|
496
|
|
|
14
|
|
|
553
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Adjustments to Interest expense, net:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Prefunded interest expenses
(1)
|
48
|
|
|
—
|
|
|
89
|
|
|
—
|
|
||||
Total Adjustments to Interest expense, net
|
48
|
|
|
—
|
|
|
89
|
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Adjustments to Income tax provision:
|
|
|
|
|
|
|
|
|
|
|
|
||||
United Kingdom tax rate change
(2)
|
—
|
|
|
—
|
|
|
(77
|
)
|
|
(178
|
)
|
||||
Tax impact of adjustments
(3)
|
(184
|
)
|
|
(263
|
)
|
|
(279
|
)
|
|
(371
|
)
|
||||
Total Adjustments to Income tax provision
|
(184
|
)
|
|
(263
|
)
|
|
(356
|
)
|
|
(549
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)
|
$
|
1,476
|
|
|
$
|
1,423
|
|
|
$
|
2,677
|
|
|
$
|
2,555
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted net earnings per common share (GAAP)
|
$
|
0.98
|
|
|
$
|
0.85
|
|
|
$
|
1.94
|
|
|
$
|
1.87
|
|
Adjustments to Operating Income
|
0.50
|
|
|
0.24
|
|
|
0.76
|
|
|
0.47
|
|
||||
Adjustments to Other income (expense)
|
0.01
|
|
|
0.46
|
|
|
0.01
|
|
|
0.50
|
|
||||
Adjustments to Interest expense, net:
|
0.04
|
|
|
—
|
|
|
0.08
|
|
|
—
|
|
||||
Adjustments to Income tax provision
|
(0.17
|
)
|
|
(0.24
|
)
|
|
(0.33
|
)
|
|
(0.50
|
)
|
||||
Adjusted diluted net earnings per common share (Non-GAAP measure)
|
$
|
1.36
|
|
|
$
|
1.31
|
|
|
$
|
2.46
|
|
|
$
|
2.34
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding, diluted
|
$
|
1,085.5
|
|
|
1,088.4
|
|
|
$
|
1,086.9
|
|
|
1,093.5
|
|
(1)
|
Presented on a pre-tax basis. The comparable prior period has been recast accordingly to reflect the tax impact of adjustments as a single adjustment. There has been no change in Net earnings attributable to Walgreens Boots Alliance, Inc., diluted net earnings per share, adjusted net earnings attributable to Walgreens Boots Alliance, Inc. or adjusted net earnings per share from those previously reported.
|
(2)
|
Discrete tax-only items.
|
(3)
|
Represents the adjustment to the GAAP basis tax provision commensurate with non-GAAP adjustments.
|
|
|
Six Months Ended
|
||||||
|
|
February 28,
2017 |
|
February 29,
2016 |
||||
Retail Pharmacy USA
|
|
$
|
378
|
|
|
$
|
386
|
|
Retail Pharmacy International
|
|
210
|
|
|
222
|
|
||
Pharmaceutical Wholesale
|
|
51
|
|
|
49
|
|
||
Total
|
|
$
|
639
|
|
|
$
|
657
|
|
Rating Agency
|
Long-Term Debt Rating
|
Commercial Paper Rating
|
Outlook
|
Fitch
|
BBB
|
F2
|
Stable
|
Moody’s
|
Baa2
|
P-2
|
On review for downgrade
|
Standard & Poor’s
|
BBB
|
A-2
|
Negative
|
Item 3.
|
Quantitative and Qualitative Disclosure about Market Risk
|
Item 4.
|
Controls and Procedures
|
Item 1.
|
Legal Proceedings
|
Item 1A.
|
Risk Factors
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
(c)
|
The following table provides information about purchases by the Company during the quarter ended
February 28, 2017
of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share purchases may be made in open market transactions, privately negotiated transactions, or pursuant to instruments and plans complying with Rule 10b5-1.
|
|
Issuer Purchases of Equity Securities
|
|||||||||||
Period
|
Total Number of Shares Purchased
|
|
Average Price Paid per Share
|
|
Total Number of Shares Purchased as Part of Publicly Announced Repurchase Programs
(1)
|
|
Approximate Dollar Value of Shares That May Yet be Purchased Under the Plans or Program
(1)
|
|||||
12/01/16 – 12/31/16
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
—
|
|
01/01/17 – 01/31/17
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
02/01/17 – 02/28/17
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Total
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
—
|
|
(1)
|
In April 2017, Walgreens Boots Alliance authorized the 2017 stock repurchase program which authorizes the purchase of up to $1.0 billion of Walgreens Boots Alliance common stock prior to the program’s expiration on December 31, 2017.
|
Item 5.
|
Other Information
|
Item 6.
|
Exhibits
|
•
|
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
|
•
|
may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
|
•
|
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
|
•
|
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.
|
Exhibit
No.
|
|
Description
|
|
SEC Document Reference
|
|
|
|
|
|
2.1*
|
|
Asset Purchase Agreement dated as of December 19, 2016 by and among Rite Aid Corporation, AFAE, LLC, Fred’s, Inc. (solely for the purposes set forth in the Asset Purchase Agreement) and Walgreens Boots Alliance, Inc. (solely for the purposes set forth in the Asset Purchase Agreement).
|
|
Filed herewith.
|
|
|
|
|
|
2.2*
|
|
Amendment No. 1, dated as of January 29, 2017, to Agreement and Plan of Merger, dated as of October 27, 2015, by and among Walgreens Boots Alliance, Inc., Victoria Merger Sub, Inc. and Rite Aid Corporation
|
|
Incorporated by reference to Exhibit 2.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on January 31, 2017.
|
|
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc.
|
|
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K12B (File No. 001-36759) filed with the SEC on December 31, 2014.
|
|
|
|
|
|
3.2
|
|
Amended and Restated Bylaws of Walgreens Boots Alliance, Inc.
|
|
Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on June 10, 2016.
|
|
|
|
|
|
10.1
|
|
Backstop Facility Commitment Letter, effective as of January 31, 2017, by and among Walgreens Boots Alliance, Inc., HSBC Securities (USA) Inc., HSBC Bank USA, National Association and HSBC Bank plc.
|
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 2, 2017.
|
|
|
|
|
|
10.2
|
|
Backstop Bridge Term Loan Credit Agreement, dated January 31, 2017, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and HSBC Bank USA, National Association, as administrative agent.
|
|
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 2, 2017.
|
|
|
|
|
|
10.3
|
|
Revolving Credit Agreement, dated February 1, 2017, by and between Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank N.A., as administrative agent.
|
|
Incorporated by reference to Exhibit 10.3 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 2, 2017.
|
|
|
|
|
|
10.4
|
|
Term Loan Credit Agreement dated February 22, 2017, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Bank of America, N.A., as administrative agent.
|
|
Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 23, 2017.
|
|
|
|
|
|
10.5
|
|
Term Loan Credit Agreement, dated February 22, 2017, by and among Walgreens Boots Alliance, Inc., the lenders from time to time party thereto and Sumitomo Mitsui Banking Corporation, as administrative agent.
|
|
Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.’s Current Report on Form 8-K (File No. 001-36759) filed with the SEC on February 23, 2017.
|
|
|
|
|
|
10.6**
|
|
Extension, dated as of March 27, 2017, to Assignment Letter between Alexander Gourlay and Walgreens Boots Alliance Services Limited.
|
|
Filed herewith.
|
|
|
|
|
|
12
|
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
Filed herewith.
|
|
|
|
|
|
31.1
|
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Filed herewith.
|
|
|
|
|
|
31.2
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Filed herewith.
|
|
|
|
|
|
32.1
|
|
Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
|
Furnished herewith.
|
|
|
|
|
|
32.2
|
|
Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
|
|
Furnished herewith.
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
Filed herewith.
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
Filed herewith.
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
Filed herewith.
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
Filed herewith.
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
Filed herewith.
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
Filed herewith.
|
|
Walgreens Boots Alliance, Inc.
|
|
(Registrant)
|
|
|
Dated: April 5, 2017
|
/s/ George R. Fairweather
|
|
George R. Fairweather
|
|
Executive Vice President and Global Chief Financial Officer
|
|
|
|
|
Dated: April 5, 2017
|
/s/ Kimberly R. Scardino
|
|
Kimberly R. Scardino
|
|
Senior Vice President, Global Controller and Chief Accounting Officer
|
|
(Principal Accounting Officer)
|
|
|
Page
|
|
|
|
ARTICLE I DEFINITIONS
|
||
|
|
|
|
Section 1.01. Certain Defined Terms
|
|
|
|
|
ARTICLE II PURCHASE AND SALE
|
||
|
|
|
|
Section 2.01. Purchased Assets
|
|
|
Section 2.02. Excluded Assets
|
|
|
Section 2.03. Assumed Liabilities
|
|
|
Section 2.04. Excluded Liabilities
|
|
|
Section 2.05. Assignment of Contracts and Rights
|
|
|
Section 2.06. Closing
|
|
|
Section 2.07. Purchase Price.
|
|
|
Section 2.08. Deliveries by Seller
|
|
|
Section 2.09. Deliveries by Buyer
|
|
|
Section 2.10. Inventory Valuation
|
|
|
Section 2.11. Prorations
|
|
|
Section 2.12. Purchased Cash; Aggregate Inventory Amount Adjustment
|
|
|
|
|
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER
|
||
|
|
|
|
Section 3.01. Incorporation, Qualification and Authority of Seller
|
|
|
Section 3.02. No Conflict
|
|
|
Section 3.03. Consents and Approvals
|
|
|
Section 3.04. Financial Information
|
|
|
Section 3.05. Absence of Certain Changes or Events
|
|
|
Section 3.06. Absence of Litigation
|
|
|
Section 3.07. Compliance with Laws
|
|
|
Section 3.08. Governmental Licenses and Permits
|
|
|
Section 3.09. Title to the Purchased Assets
|
|
|
Section 3.10. Taxes
|
|
|
Section 3.11. Employment and Employee Benefits Matters
|
|
|
Section 3.12. Real Property
|
|
|
Section 3.13. Inventory
|
|
|
Section 3.14. Environmental Matters
|
|
|
Section 3.15. Privacy and Data Security; Seller Rx Data
|
|
|
Section 3.16. Compliance with Health Care Legal Requirements
|
|
|
Section 3.17. Brokers
|
|
|
Section 3.18. Condition and Sufficiency of Purchased Assets
|
|
|
Section 3.19. No Other Representations or Warranties
|
|
|
|
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER
|
||
|
|
|
|
Section 4.01. Organization and Authority of Buyer
|
|
|
Section 4.02. Qualification of Buyer
|
|
|
Section 4.03. No Conflict
|
|
|
Section 4.04. Consents and Approvals
|
|
|
Section 4.05. Absence of Litigation; Compliance with Laws
|
|
|
Section 4.06. Absence of Restraints; Compliance With Laws
|
|
|
Section 4.07. Financial Ability
|
|
|
Section 4.08. Solvency
|
|
|
Section 4.09. Brokers
|
|
|
Section 4.10. Investigation
|
|
|
|
|
ARTICLE V ADDITIONAL AGREEMENTS
|
||
|
|
|
|
Section 5.01. Conduct of Business Prior to the Applicable Closing
|
|
|
Section 5.02. Access to Information
|
|
|
Section 5.03. Preservation of Books and Records
|
|
|
Section 5.04. Confidentiality
|
|
|
Section 5.05. Regulatory and Other Authorizations; Consents.
|
|
|
Section 5.06. Use of Names
|
|
|
Section 5.07. Taxes.
|
|
|
Section 5.08. Ancillary Agreements
|
|
|
Section 5.09. Further Action
|
|
|
Section 5.10. Solvency After Closing
|
|
|
Section 5.11. Non-Solicitation of Employees
|
|
|
Section 5.12. Financing.
|
|
|
Section 5.13. Destruction of Purchased Assets; Store Removal
|
|
|
Section 5.14. Restriction on Use of Customer Data
|
|
|
Section 5.15. Commercial Assistance
|
|
|
Section 5.16. Conversion of Stores
|
|
|
Section 5.17. RediClinic
|
|
|
Section 5.18. Acquired Leases
|
|
|
Section 5.19. Duplicate IT System
|
|
|
|
|
ARTICLE VI EMPLOYEE MATTERS
|
||
|
|
|
|
Section 6.01. Employee Matters
|
|
|
|
|
ARTICLE VII CONDITIONS TO CLOSING
|
||
|
|
|
|
Section 7.01. Conditions to Obligations of Parent and Seller
|
|
|
Section 7.02. Conditions to Obligations of Buyer
|
|
|
Section 7.03. Frustration of Closing Conditions
|
|
|
|
|
ARTICLE VIII TERMINATION, AMENDMENT AND WAIVER
|
||
|
|
|
|
Section 8.01. Termination
|
|
|
Section 8.02. Notice of Termination
|
|
|
Section 8.03. Effect of Termination
|
|
|
Section 8.04. Extension; Waiver; Rescission
|
|
|
|
|
ARTICLE IX INDEMNIFICATION
|
||
|
|
|
|
Section 9.01. Indemnification by Seller
|
|
|
Section 9.02. Indemnification by Buyer
|
|
|
Section 9.03. Notification of Claims
|
|
|
Section 9.04. Exclusive Remedies
|
|
|
Section 9.05. Additional Indemnification Provisions
|
|
|
Section 9.06. Mitigation
|
|
|
Section 9.07. Third Party Remedies
|
|
|
Section 9.08. Limitation on Liability
|
|
|
Section 9.09. Parent Guaranty.
|
|
|
Section 9.10. Fred’s Guaranty.
|
|
|
|
|
ARTICLE X GENERAL PROVISIONS
|
||
|
|
|
|
Section 10.01. Survival
|
|
|
Section 10.02. Expenses
|
|
|
Section 10.03. Notices
|
|
|
Section 10.04. Public Announcements
|
|
|
Section 10.05. Severability
|
|
|
Section 10.06. Entire Agreement
|
|
|
Section 10.07. Assignment
|
|
|
Section 10.08. No Third-Party Beneficiaries
|
|
|
Section 10.09. Amendment
|
|
|
Section 10.10. Disclosure Schedules
|
|
|
Section 10.11. Governing Law; Submission to Jurisdiction
|
|
|
Section 10.12. Bulk Sales Laws
|
|
|
Section 10.13. Specific Performance
|
|
|
Section 10.14. Interpretation
|
|
|
Section 10.15. Counterparts
|
|
|
Section 10.16. Waiver of Jury Trial
|
|
|
Section 10.17. Non-Recourse
|
|
|
Section 10.18. Time is of the Essence
|
2.01(l)
|
Intellectual Property
|
2.02(p)
|
Excluded Assets
|
2.07
|
Allocation of the Base Purchase Price
|
2.11
|
Prorations
|
3.02
|
No Conflict
|
3.04
|
Financial Information
|
3.06
|
Absence of Litigation
|
3.07
|
Compliance with Laws
|
3.11(a)
|
Employee Plans and Employee Benefits Matters
|
3.11(b)
|
Multiemployer Plans
|
3.11(f)
|
Collective Bargaining Agreements
|
3.12(a)
|
Owned Real Property
|
3.12(b)
|
Leased Real Property
|
3.13
|
Inventory: Liens and Permitted Liens
|
3.14
|
Environmental Matters
|
3.16(c)
|
Compliance with Health Care Legal Requirements
|
3.18
|
Sufficiency of Purchased Assets
|
5.01
|
Conduct of Business Prior to the Applicable Closing
|
5.05(e)
|
Pricing Methodology
|
5.15
|
License Agreements
|
5.16
|
Conversion of Stores
|
6.01(b)
|
Open Positions
|
6.01(j)(iv)
|
Multiemployer Plan Withdrawal Liability
|
7.01(b)
|
Governmental Approvals
|
Exhibit A
|
Definitions
|
Exhibit B
|
Transaction Accounting Principles
|
Exhibit C
|
Form of Transition Services Agreement
|
Exhibit D-1
|
Form of Bill of Sale, Assignment and Assumption Agreement
|
Exhibit D-2
|
Form of Subsequent Closing Bill of Sale, Assignment and Assumption Agreement
|
Exhibit E
|
Inventory Procedures
|
Exhibit F
|
Form of Transitional Trademark License Agreement
|
Exhibit G
|
Form of Trademark Assignment Agreement
|
Schedule 2.10(b)
|
Form of Physical Inventory Valuation Report
|
Schedule A
|
Inventory Valuation Process Example
|
Schedule B
|
Duplicate IT System Exceptions
|
By:
|
/s/ James J. Comitale
|
|
Name: James J. Comitale
|
|
Title: Senior Vice President, General Counsel & Secretary
|
By:
|
/s/ Mark Vainisi
|
|
Name: Mark Vainisi
|
|
Title: Senior Vice President, WBA Mergers & Acquisitions
|
By:
|
/s/ Michael K. Bloom
|
|
Name: Michael K. Bloom
|
|
Title: President and Chief Executive Officer
|
By:
|
/s/ Michael K. Bloom
|
|
Name: Michael K. Bloom
|
|
Title: President and Chief Executive Officer
|
1.
|
Paragraph 1 of the Agreement is amended to reflect your current title, Co-Chief Operating Officer of Walgreens Boots Alliance, Inc. (“WBA”), reporting directly to the Chief Executive Officer of WBA.
|
2.
|
Paragraph 6(a) of the Agreement is amended to reflect your current annual rate of salary, £704,330.
|
|
Six Months Ended,
|
|
Twelve Months Ended,
|
||||||||||||||||||||
|
February 28, 2017
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||||
Income before income tax provision
|
$
|
2,567
|
|
|
$
|
5,144
|
|
|
$
|
5,311
|
|
|
$
|
3,557
|
|
|
$
|
4,047
|
|
|
$
|
3,376
|
|
Add:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Minority Interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5
|
|
|
—
|
|
||||||
Fixed Charges
|
1,171
|
|
|
2,367
|
|
|
2,054
|
|
|
1,376
|
|
|
1,383
|
|
|
1,260
|
|
||||||
Amortization of capitalized interest
|
—
|
|
|
—
|
|
|
1
|
|
|
6
|
|
|
7
|
|
|
6
|
|
||||||
Less:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Equity earnings
|
(26
|
)
|
|
(37
|
)
|
|
(315
|
)
|
|
(617
|
)
|
|
(496
|
)
|
|
—
|
|
||||||
Capitalized interest
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(6
|
)
|
|
(7
|
)
|
|
(9
|
)
|
||||||
Earnings as defined
|
$
|
3,712
|
|
|
$
|
7,474
|
|
|
$
|
7,050
|
|
|
$
|
4,316
|
|
|
$
|
4,939
|
|
|
$
|
4,633
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Interest expense, net of capitalized interest
|
$
|
345
|
|
|
$
|
628
|
|
|
$
|
632
|
|
|
$
|
168
|
|
|
$
|
193
|
|
|
$
|
94
|
|
Capitalized interest
|
—
|
|
|
—
|
|
|
1
|
|
|
6
|
|
|
7
|
|
|
9
|
|
||||||
Portions of rentals representative of the interest factor
|
825
|
|
|
1,739
|
|
|
1,421
|
|
|
1,202
|
|
|
1,183
|
|
|
1,157
|
|
||||||
Fixed charges as defined
|
$
|
1,171
|
|
|
$
|
2,367
|
|
|
$
|
2,054
|
|
|
$
|
1,376
|
|
|
$
|
1,383
|
|
|
$
|
1,260
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Ratio of earnings to fixed charges
|
3.17
|
|
|
3.16
|
|
|
3.43
|
|
|
3.14
|
|
|
3.57
|
|
|
3.68
|
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
/s/
|
Stefano Pessina
|
|
Chief Executive Officer
|
Date: April 5, 2017
|
|
Stefano Pessina
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
/s/
|
George Fairweather
|
|
Global Chief Financial Officer
|
Date: April 5, 2017
|
|
George Fairweather
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|